文献速递消化、代谢与肾脏急症

大承气汤通过调节肠道菌群减轻轻症急性胰腺炎患者炎症反应并促进胃肠功能恢复

[Dachengqi decoction reduces inflammatory response and promotes recovery of gastrointestinal function in patients with mild acute pancreatitis by regulating the intestinal microbiota].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2023-01-01
一句话结论在轻症急性胰腺炎患者中,常规治疗联用大承气汤(100 mL/次,每日2次,连用7天)可降低CRP、PCT、IL-6并缩短排气、肠鸣音恢复和排便时间。

该平行随机对照试验纳入上海中医药大学附属中西医结合医院2018年3月至2021年2月收治的68例急性胰腺炎患者,最终48例轻症急性胰腺炎(MAP)患者入组,常规治疗组24例、大承气汤组24例,另招募20名健康志愿者作对照。两组均接受奥曲肽、禁食、胃肠减压等西医常规治疗,大承气汤组加用大承气汤口服100 mL/次、每日2次、连用7天。治疗7天时大承气汤组CRP、PCT、IL-6均显著低于常规治疗组,首次排气时间、肠鸣音恢复时间、首次排便时间均显著短于常规治疗组。肠道菌群多样性以健康对照组最高、常规治疗组最低,LEfSe分析显示大承气汤降低大肠埃希菌-志贺菌和产气荚膜梭菌相对丰度、增加乳酸杆菌、Rombutzia和Brutella相对丰度。治疗期间血、尿、粪、肾功能及心电图未见明显异常。

要点

  • MAP患者加用大承气汤口服100 mL/次、每日2次、连用7天,治疗7天时CRP 8.50(3.50, 13.00)mg/L vs 常规治疗组16.00(9.25, 29.75)mg/L,P<0.05。
  • 大承气汤组PCT 0.06(0.03, 0.08)μg/L vs 常规治疗组0.09(0.05, 0.11)μg/L,IL-6 6.36(3.96, 10.79)ng/L vs 13.24(6.69, 18.87)ng/L,均P<0.05。
  • 大承气汤组首次排气时间1.62±0.65天 vs 常规治疗组2.80±0.65天,肠鸣音恢复时间1.13±0.58天 vs 2.31±0.76天,首次排便时间3.12±0.75天 vs 4.39±0.76天,均P<0.05。
  • 大肠埃希菌-志贺菌与WBC、CRP、PCT、IL-6正相关有统计学意义(r分别为0.31、0.41、0.57、0.43,均P<0.05),其他菌与炎症指标无显著相关。
  • 治疗期间MAP患者血、尿、粪常规、肾功能及心电图未见明显异常。

适用人群与场景

  • 上海中医药大学附属中西医结合医院2018年3月至2021年2月收治的急性胰腺炎患者,最终纳入轻症急性胰腺炎(MAP)48例,常规治疗组24例、大承气汤组24例;另招募20名健康志愿者作对照。
  • 排除中重度急性胰腺炎16例,未采集或自愿放弃治疗4例。

处置流程与药物剂量

  • 两组患者均接受奥曲肽、禁食、胃肠减压、退热镇痛、抗炎、抑制胃酸和胰液分泌、维持电解质平衡等西医常规治疗。
  • 大承气汤组在常规治疗基础上口服大承气汤,100 mL/次,每日2次,连用7天。

研究设计与关键结果

  • 平行随机对照试验,最终纳入48例MAP患者(常规治疗组24例、大承气汤组24例)及20名健康志愿者;两组治疗7天时炎症指标均较治疗前显著降低。
  • 大承气汤组CRP 8.50(3.50, 13.00)mg/L vs 常规治疗组16.00(9.25, 29.75)mg/L,PCT 0.06(0.03, 0.08)μg/L vs 0.09(0.05, 0.11)μg/L,IL-6 6.36(3.96, 10.79)ng/L vs 13.24(6.69, 18.87)ng/L,均P<0.05。
  • 大承气汤组首次排气时间1.62±0.65天 vs 常规治疗组2.80±0.65天,肠鸣音恢复时间1.13±0.58天 vs 2.31±0.76天,首次排便时间3.12±0.75天 vs 4.39±0.76天,均P<0.05。
  • 肠道菌群多样性及丰度健康对照组最高、常规治疗组最低;健康对照组与MAP患者菌群重合度小,不同治疗方式MAP患者间重合度较大。
  • LEfSe分析显示大承气汤降低大肠埃希菌-志贺菌和产气荚膜梭菌相对丰度,增加乳酸杆菌、Rombutzia和Brutella三种有益菌相对丰度;MAP患者肠道中黏液乳杆菌和凝结乳杆菌显著富集。
  • 相关性分析显示大肠埃希菌-志贺菌与WBC、CRP、PCT、IL-6正相关有统计学意义(r分别为0.31、0.41、0.57、0.43,均P<0.05),其他菌与炎症指标无显著相关。
  • 治疗期间MAP患者血、尿、粪样本、肾功能及心电图未见明显异常。

证据类型、等级与局限

  • 证据类型:平行随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为大承气汤可通过调节肠道菌群组成减轻MAP患者炎症反应、促进肠道微生态平衡和胃肠功能恢复,治疗期间未见明显不良反应。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the therapeutic effect and mechanism of Dachengqi decoction on patients with mild acute pancreatitis (MAP).

METHODS: A parallel randomized controlled trial was conducted. Sixty-eight patients with acute pancreatitis (AP) admitted to Shanghai Traditional Chinese Medicine (TCM)-Integrated Hospital from March 2018 to February 2021 were enrolled. Referring to the condition on admission of the patients and whether they agreed to receive the Dachengqi decoction or not, they were divided into conventional treatment group and Dachengqi decoction group according to the principle of 1:1 equal randomness. Meanwhile, 20 healthy volunteers were recruited as controls. Both groups of patients were treated with octreotide, fasting, gastrointestinal decompression, antipyretic and analgesic, anti-inflammatory, inhibition of gastric acid and pancreatic juice secretion, maintenance of electrolyte balance and other western conventional medicine. The patients in the Dachengqi decoction group received Dachengqi decoction orally on the basis of routine treatment, 100 mL each time, twice a day, for seven consecutive days. The inflammation parameters [white blood cell count (WBC), C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6)] before and after treatment and the recovery time of gastrointestinal function (first exhaust time, time to recover bowel sounds, first defecation time) of patients were recorded. 16S rRNA gene sequencing of stool samples was recorded, and normalized data were obtained after quality control and other related processing. The data were subjected to diversity analysis (Alpha diversity and Beta diversity) and linear discriminant analysis effect size analysis (LEfSe analysis) to observe changes in the gut microbiota of MAP patients. Spearman rank correlation coefficient was used to analyze the correlation between inflammatory indexes and microorganisms at the intestinal genus level. Blood, urine, stool samples, renal function, and electrocardiogram (ECG) during treatment of MAP patients were detected to assess the safety of the treatment.

RESULTS: Of the 68 patients with AP, 16 were excluded from moderate-severe AP, 4 were not collected or voluntarily abandoned treatment. Finally, 48 patients with MAP were enrolled, 24 in the conventional treatment group and 24 in the Dachengqi decoction group. The inflammation parameters levels at 7 days of treatment in both groups were significantly lower than those before treatment. CRP, PCT and IL-6 levels in the Dachengqi decoction group were significantly lower than those in the conventional treatment group [CRP (mg/L): 8.50 (3.50, 13.00) vs. 16.00 (9.25, 29.75), PCT (μg/L): 0.06 (0.03, 0.08) vs. 0.09 (0.05, 0.11), IL-6 (ng/L): 6.36 (3.96, 10.79) vs. 13.24 (6.69, 18.87), all P < 0.05]. The first exhaust time, time to recover bowel sounds and first defecation time in the Dachengqi decoction group were significantly shorter than those in the conventional treatment group [first exhaust time (days): 1.62±0.65 vs. 2.80±0.65, time to recover bowel sounds (days): 1.13±0.58 vs. 2.31±0.76, first defecation time (days): 3.12±0.75 vs. 4.39±0.76, all P < 0.05]. The analysis of intestinal microflora diversity showed that both the diversity and abundance of microbial communities were the highest in the healthy control group and the lowest in the conventional treatment group. In addition, the coincidence degree of microbial communities in healthy controls and MAP patients was small, while the coincidence degree of MAP patients among different treatment methods was relatively large. LEfSe analysis showed that Dachengqi decoction reduced the relative abundance of Escherichia coli-Shigella and Clostridium erysipelae, and increased the relative abundance of three beneficial bacteria, namely Lactobacillus, Rombutzia and Brutella. In the intestines of MAP patients, Lactobacillus mucilaginus and Lactobacillus conjunctus were significantly enriched. Correlation analysis showed that positive correlations between Escherichia coli-Shigella and the four inflammatory indicators including WBC, CRP, PCT, IL-6 were statistically significant (r value was 0.31, 0.41, 0.57, 0.43, respectively, all P < 0.05). There was no significant correlation between other bacteria and inflammatory indicators. During the treatment, there was no obvious abnormality in blood, urine and feces, renal function and ECG of MAP patients.

CONCLUSIONS: Dachengqi decoction could reduce inflammatory responses and promote recovery of intestinal microecological balance and gastrointestinal function in patients with MAP by regulating the composition of intestinal flora. No significant adverse effects were observed during the treatment period.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Li J, Dai Y, Cao H, et al. [Dachengqi decoction reduces inflammatory response and promotes recovery of gastrointestinal function in patients with mild acute pancreatitis by regulating the intestinal microbiota]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 36916377. doi:10.3760/cma.j.cn121430-20220921-00852

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。